For the quarter ending 2025-09-30, OPRX had $2,934K increase in cash & cash equivalents over the period. $3,192K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income (loss) | 779 | -667 |
| Depreciation and amortization | 1,081 | 2,168 |
| Stock-based compensation | 1,956 | 3,046 |
| Goodwill impairment | 0 | - |
| Bad debt expense | 0 | 0 |
| Amortization of debt issuance costs | 174 | 611 |
| Accounts receivable | -1,285 | -4,700 |
| Prepaid expenses and other assets | -510 | 958 |
| Accounts payable | 55 | -174 |
| Revenue share payable | -262 | -2,462 |
| Accrued expenses and other liabilities | -2,225 | 4,138 |
| Operating lease liabilities | 6 | 9 |
| Deferred tax liabilities | -1,033 | 1,033 |
| Taxes receivable and payable | -1,101 | -964 |
| Deferred revenue | -89 | 11 |
| Net cash provided by operating activities | 3,202 | 8,425 |
| Purchase of property and equipment | 10 | 37 |
| Capitalized software development costs | 0 | 91 |
| Net cash used in investing activities | -10 | -128 |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | 188 | - |
| Proceeds from exercise of stock options | 338 | - |
| Repayment of long-term debt | 500 | 5,000 |
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | - | 92 |
| Net cash used in financing activities | -258 | -5,092 |
| Net increase in cash and cash equivalents | 2,934 | 3,205 |
| Cash and cash equivalents at beginning of period | 13,380 | - |
| Cash and cash equivalents at end of period | 19,519 | - |
OptimizeRx Corp (OPRX)
OptimizeRx Corp (OPRX)